PRCT

PROCEPT BioRobotics Corp. (PRCT) | Rumor.io

PROCEPT BioRobotics

PRCT

Attention (50-day avg)0%

Attention rank (50-day avg)#958

Bullish sentiment (50-day avg)55%

Price to earnings ratio-10

Market capitalization988M

Earnings per share-1.95

Dividend yield (TTM)2.79%

Revenue (annual)308.1M

Net income (annual)-95.6M

Social

What share of all stock conversation is about PRCT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0.01% +0.01

Jun 7

PROCEPT BioRobotics Corporation's ($PRCT) decentralized infrastructure has spread across 150+ countries with 800K+ nodes.
This decentralized infrastructure cannot be built by a centralized team, highlighting a key aspect of the company's approach.
The post suggests that $PRCT is building something distinct in the Web3 space.

Generated by AI

Sentiment

Of the messages about PRCT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	15.38%	17.65% -45.9	76.73% -17.51
Bearish	—	84.62%	82.35% +45.9	23.27% +17.51

Oct 28

PROCEPT BioRobotics Corporation's ($PRCT) Q3 revenue growth of 66% and record gross margins of 63.2% exceeded expectations, driving a 26% surge in the stock.
The company's strong earnings report, including a 574% increase in average volume, has cleared a multi-month base and pushed the stock into all-time highs.
$PRCT's AI-powered bio-robotics are making strides in treating prostate issues, with the company projecting full-year 2024 revenue of $222.5-223.0 million, a significant increase from previous guidance.

Generated by AI

Topics

Of the messages about PRCT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	5.77%	0.92%
Technical Analysis	—	—	88.46%	0.34%
Macro	—	—	0%	49.28%
Controversies	—	—	5.77%	0.01%
Earnings	—	—	0%	0.06%
Analysts	—	—	0%	49.39%

Earnings· Oct 28

PROCEPT BioRobotics Corporation reported Q3 revenue of $58.4 million, a 66% increase from the prior period in 2023, driven by increased demand and higher average selling prices.
The company's Q3 revenue beat estimates of $53.2 million, and its earnings per share (EPS) of $(0.40) also beat estimates of $(0.49).
PROCEPT BioRobotics increased its full-year 2024 revenue guidance to $222.5-$223.0 million, up from previous guidance of $217.0 million, and also raised its gross margin guidance to approximately 61%.

Analysts· Mar 9

Guggenheim Securities lowered the price target for PRCT to $40 from $55 due to recent peer group multiple compression, citing strong Q results and impressive momentum in handpiece shipments.
SVB Leerink raised the price target for PRCT to $30 from $25, maintaining an Outperform rating, and Bank of America lowered the price target to $42 from $48, maintaining a Buy rating.
BofA Securities analyst Craig Bijou maintains a Buy rating for PRCT with a lower price target of $42, citing accelerating adoption trends, including high robot-to-new-account ratios and current surgeons broadening use.

Announcements· Oct 28

PROCEPT BioRobotics reported a Q3 net loss of $0.40 per diluted share, beating analyst expectations of a loss of $0.49.
The company raised its FY24 revenue guidance to $222.5M-$223M, up from previous guidance of $217M, driven by strong revenue growth and expanded U.S. and international sales.
PROCEPT BioRobotics reported Q3 revenue of $58.4 million, up 66% year-over-year, driven by higher U.S. system sales, consumable sales, and strong international growth.

Generated by AI

Community

Of the messages about PRCT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	70.51%	82.15%	11.19%
Newcomers	—	29.49%	17.85%	88.81%

Regulars· Oct 28

$PRCT Procept BioRobotics gapped 30% higher on 1500% above average volume after reporting Q3 revenue of $58.4M, beating consensus estimates.
The company's strong quarterly results, including 66% annual revenue growth and record gross margins of 63.2%, are expected to drive substantial growth in 2024.
PROCEPT BioRobotics' proposed offering of common stock is expected to raise revenue guidance to $222.5M-$223M, with the company reporting a narrowed loss of $21M and better-than-expected revenue.

Newcomers· Mar 10

A director at PROCEPT BioRobotics Corp purchased $10.48M in shares, increasing their holdings by 860% and lifting their stake to ~0.76% of the company.
This purchase comes after a ~57% 1-year drawdown, and the director spent about $24.55 on average, making it a significant buy.
The insider buy is seen as a signal of faith in the company's prospects, particularly after a recent earnings dip and reset of the 2026 guide, with projected revenue growth of 27-33% and procedure growth of 39-48%.

Generated by AI

News

Procept BioRobotics extends loan maturity date with CIBC by one year

5d agoInvesting.com

Kaplan Fox Continues to Alert Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a Class Action Deadline on September 22, 2026

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Seeking Recovery to Contact the Firm Before September 22, 2026

Detailed price information for Procept Biorobotics Corp (PRCT-Q) from The Globe and Mail including charting and trades.

8d agoThe Globe and Mail

Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 22, 2026

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

11d agotheglobeandmail.com

Kaplan Fox Reminds Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a Securities Class Action Deadline - Contact the Firm Before September 22, 2026

12d agobarchart.com

Planet 13 Announces Q2 2021 Financial Results

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

14d agoThe Globe and Mail

Also Discussed

Investors talking about PRCT also mention

#	Name	Attention
1	TransMedics Group, Inc.TMDX	0%-0.01
2	Intuitive Surgical Inc.ISRG	0%0
3	PTVE - Pactiv Evergreen Inc.	——
4	Arbe Robotics Ltd.ARBE	0%0
5	Liberty Broadband CorporationLBRDA	0%0
6	SWAV - ShockWave Medical, Inc.	——
7	Harrow Inc.HROW	0%0
8	TaskUs, Inc. Class A Common StockTASK	0%new
9	Glacier Bancorp Inc.GBCI	0%0
10	TWKS - Thoughtworks Holding, Inc.	——

PROCEPT BioRobotics Corp.

Healthcare
Medical Devices

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on urology. The company develops, manufactures, and sells the AquaBeam Robotic System and the HYDROS Robotic System, both designed for image-guided, minimally invasive urologic procedures. Its core offering is Aquablation therapy, a robotic treatment approach used primarily for benign prostatic hyperplasia and related lower urinary tract symptoms. PROCEPT BioRobotics also supports its systems with consumables, service, and clinical workflow tools that help hospitals and urology practices deliver precise, patient-specific care. The company serves healthcare providers in the United States and selected international markets, positioning itself within the medical device and surgical robotics segments of the healthcare industry.

Website

Location

150 Baytech Drive

San Jose, CA, 95134

United States

Social

What share of all stock conversation is about PRCT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0.01% +0.01

Jun 7

PROCEPT BioRobotics Corporation's ($PRCT) decentralized infrastructure has spread across 150+ countries with 800K+ nodes.
This decentralized infrastructure cannot be built by a centralized team, highlighting a key aspect of the company's approach.
The post suggests that $PRCT is building something distinct in the Web3 space.

Generated by AI

Sentiment

Of the messages about PRCT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	15.38%	17.65% -45.9	76.73% -17.51
Bearish	—	84.62%	82.35% +45.9	23.27% +17.51

Oct 28

PROCEPT BioRobotics Corporation's ($PRCT) Q3 revenue growth of 66% and record gross margins of 63.2% exceeded expectations, driving a 26% surge in the stock.
The company's strong earnings report, including a 574% increase in average volume, has cleared a multi-month base and pushed the stock into all-time highs.
$PRCT's AI-powered bio-robotics are making strides in treating prostate issues, with the company projecting full-year 2024 revenue of $222.5-223.0 million, a significant increase from previous guidance.

Generated by AI

Topics

Of the messages about PRCT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	5.77%	0.92%
Technical Analysis	—	—	88.46%	0.34%
Macro	—	—	0%	49.28%
Controversies	—	—	5.77%	0.01%
Earnings	—	—	0%	0.06%
Analysts	—	—	0%	49.39%

Earnings· Oct 28

PROCEPT BioRobotics Corporation reported Q3 revenue of $58.4 million, a 66% increase from the prior period in 2023, driven by increased demand and higher average selling prices.
The company's Q3 revenue beat estimates of $53.2 million, and its earnings per share (EPS) of $(0.40) also beat estimates of $(0.49).
PROCEPT BioRobotics increased its full-year 2024 revenue guidance to $222.5-$223.0 million, up from previous guidance of $217.0 million, and also raised its gross margin guidance to approximately 61%.

Analysts· Mar 9

Guggenheim Securities lowered the price target for PRCT to $40 from $55 due to recent peer group multiple compression, citing strong Q results and impressive momentum in handpiece shipments.
SVB Leerink raised the price target for PRCT to $30 from $25, maintaining an Outperform rating, and Bank of America lowered the price target to $42 from $48, maintaining a Buy rating.
BofA Securities analyst Craig Bijou maintains a Buy rating for PRCT with a lower price target of $42, citing accelerating adoption trends, including high robot-to-new-account ratios and current surgeons broadening use.

Announcements· Oct 28

PROCEPT BioRobotics reported a Q3 net loss of $0.40 per diluted share, beating analyst expectations of a loss of $0.49.
The company raised its FY24 revenue guidance to $222.5M-$223M, up from previous guidance of $217M, driven by strong revenue growth and expanded U.S. and international sales.
PROCEPT BioRobotics reported Q3 revenue of $58.4 million, up 66% year-over-year, driven by higher U.S. system sales, consumable sales, and strong international growth.

Generated by AI

Community

Of the messages about PRCT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	70.51%	82.15%	11.19%
Newcomers	—	29.49%	17.85%	88.81%

Regulars· Oct 28

$PRCT Procept BioRobotics gapped 30% higher on 1500% above average volume after reporting Q3 revenue of $58.4M, beating consensus estimates.
The company's strong quarterly results, including 66% annual revenue growth and record gross margins of 63.2%, are expected to drive substantial growth in 2024.
PROCEPT BioRobotics' proposed offering of common stock is expected to raise revenue guidance to $222.5M-$223M, with the company reporting a narrowed loss of $21M and better-than-expected revenue.

Newcomers· Mar 10

A director at PROCEPT BioRobotics Corp purchased $10.48M in shares, increasing their holdings by 860% and lifting their stake to ~0.76% of the company.
This purchase comes after a ~57% 1-year drawdown, and the director spent about $24.55 on average, making it a significant buy.
The insider buy is seen as a signal of faith in the company's prospects, particularly after a recent earnings dip and reset of the 2026 guide, with projected revenue growth of 27-33% and procedure growth of 39-48%.

Generated by AI

PROCEPT BioRobotics

Social

Jun 7

Oct 28

Earnings· Oct 28

Analysts· Mar 9

Announcements· Oct 28

Regulars· Oct 28

Newcomers· Mar 10

Procept BioRobotics extends loan maturity date with CIBC by one year

Kaplan Fox Continues to Alert Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a Class Action Deadline on September 22, 2026

Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Seeking Recovery to Contact the Firm Before September 22, 2026

Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 22, 2026

Kaplan Fox Reminds Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a Securities Class Action Deadline - Contact the Firm Before September 22, 2026

Planet 13 Announces Q2 2021 Financial Results

Also Discussed

PROCEPT BioRobotics Corp.

Company Information

Location

Procept BioRobotics extends loan maturity date with CIBC by one year

Kaplan Fox Continues to Alert Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a Class Action Deadline on September 22, 2026

Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Seeking Recovery to Contact the Firm Before September 22, 2026

Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 22, 2026

Kaplan Fox Reminds Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) to a Securities Class Action Deadline - Contact the Firm Before September 22, 2026

Planet 13 Announces Q2 2021 Financial Results

Also Discussed

Social

Jun 7

Oct 28

Earnings· Oct 28

Analysts· Mar 9

Announcements· Oct 28

Regulars· Oct 28

Newcomers· Mar 10